Coya Therapeutics, Inc. (COYA) - Q2 2026 Filing Summary
Business Context and Reporting Period
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies to enhance Regulatory T cell (Treg) function for neurodegenerative, autoimmune, and metabolic diseases. This Form 10-Q covers the quarterly period ended June 30, 2026. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 7, 2026, there were 23,457,849 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $243,745 | $494,892 | $421,500 |
| Net Loss | $(6,638,260) | $(13,845,250) | $(13,401,734) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.60) | $(0.80) |
| Cash and Cash Equivalents (End of Period) | $43,181,002 | $43,181,002 | $29,757,328 |
| Accumulated Deficit | $(75,808,527) | $(75,808,527) | $(54,138,904) |
| Operating Cash Flow (YTD) | $(13,584,446) | $(13,584,446) | $(8,601,571) |
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by $73,392 (17.4%) year-over-year for the six months ended June 30, driven by the recognition of R&D services revenue under the DRL Development Agreement.
- Expense Shifts: Research and Development (R&D) expenses increased by $250,068 YTD. This was primarily due to a $0.7 million increase in internal R&D expenses, partially offset by decreases in sponsored research and preclinical product candidate costs. The shift reflects the transition of COYA 302 from preclinical to clinical development (Phase 2 ALS trial).
- Financing Activity: In January 2026, the company completed a private placement raising approximately $11.1 million (net proceeds of $10.95 million). This significantly improved liquidity compared to the prior year period which had no significant financing inflows.
- Stock-Based Compensation: Total stock-based compensation expense increased to $3.14 million YTD 2026 from $2.12 million YTD 2025. This includes a $1.0 million incremental charge related to the modification of stock options for the former Executive Chairman upon resignation.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that cash of $43.2 million is expected to fund operations into the second half of 2027. However, the company has incurred losses since inception and anticipates needing substantial additional financing to fund operations and commercial development. The financial statements are prepared on a going-concern basis.
- Capital Resources: The company established an At-The-Market (ATM) Offering Program in May 2026 with Leerink Partners LLC, allowing for the sale of up to $30.0 million of common stock. No shares have been sold under this program as of June 30, 2026.
- Development Milestones: On May 11, 2026, the FDA granted Fast Track Designation to COYA 302 for the treatment of ALS. The company is currently conducting the ALSTARS Trial (Phase 2) for ALS.
- Risks: Key risks include the inability to raise additional capital, dependence on the DRL collaboration for revenue, the uncertainty of clinical trial outcomes, and the need to monetize intellectual property within five years under the Methodist License Agreement to avoid termination.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management estimate that current cash ($43.2M) will sustain operations into late 2027, given the high burn rate (~$13.6M operating cash outflow in 6 months).
- Collaboration Revenue Recognition: Review the specific inputs used for the "inputs approach" in recognizing revenue from the DRL Development Agreement to ensure consistency with budgeted vs. actual COYA 302 expenses.
- ATM Program Utilization: Monitor future filings for sales under the $30M ATM program, as this will be a primary source of near-term liquidity.
- License Obligations: Confirm the status of the five-year monetization deadline for the Methodist License Agreement and the potential termination risks if commercialization does not occur.
- Stock-Based Compensation: Assess the impact of the $1.0 million one-time charge for the former Executive Chairman's option modification on future expense projections.